Pluristem Therapeutics Inc (PSTI)

[Scott999]

When looking at the benefits of Orphan Drug Designation yesterday I came across an articles which had the following paragraph.

There is an even greater potential for profit when drugs have multiple orphan disease indications or if they can later go on to be used for more widespread non-orphan indications; for example, Gleevec® from Novartis Oncology resulted in sales of $2.4 billion in 2010. In addition, a number orphan drugs are biologics, meaning they are less likely to have generic equivalents, which extends the value to sponsors even after patent expiration.

https://criteriuminc.com/wordpress/index.php/orphan-drug-development-why-they-are-so-important/

And from that article just posted

Aberman said this approval could fast-track the cell product use for other indications relating to damaged hematological systems, including failed bone-marrow transplants, blood disorders because of prolonged chemotherapy or radiation treatment, and genetic blood disorders or related cancers. Collectively, this would mean improved treatment for millions of people.

If they could just get this contract completed and get this phase 3 NHP trial started, other indications could come on line soon after upon having good results and getting it approved.

13000 in the U.S. alone have this type of blood disorder. It's was great to see quotes from Prof. Or, who actually administered the treatment. Sure all three died eventually, but to go from deathbed to discharged and having an extra 9 months (I believe) to live is amazing. And who knows, regular administration of PLX may have prolonged their life substantially more.

Cmon get this contract signed so we can get the Plx show on the road.